Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

Conditions: Esophageal Squamous Cell Carcinoma; Neoadjuvant Chemoimmunotherapy; Adjuvant Therapy Interventions: Drug: Tislelizumab Sponsors: Guo Xufeng Recruiting

https://clinicaltrials.gov/study/NCT06056336

Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials